Ambrohexal, tablets 30 mg 20 pcs

Ambrohexal is a medicinal product with mucolytic, secretolytic and expectorant action, and the active ingredient of the drug is ambroxol.

The mechanism of action of this drug is associated with reduction of sputum viscosity as a result of depolymerization of sputum mucopolysaccharides, which consists in breaking disulfide bonds in molecules, increasing release of active hydrolyzing enzymes from Clark cells.

Ambrohexal also increases the activity of the cilia of the bronchial epithelium, and normalizes the ratio of all components of sputum and in this regard stimulates its mucociliary transport. This facilitates expectoration of sputum from the respiratory tract and stimulates secretion and blockage of surfactant breakdown.

Ambrohexal is rapidly absorbed from the gastrointestinal tract with high absorption capacity, and its optimal plasma concentration is reached within two hours after taking the drug: tablets, syrup, sustained release capsules and inhalation solution.

The action of the drug starts after 30 minutes after taking the syrup or tablets and depends on the speed of absorption of the drug in the stomach and intestines. The drug is metabolized in the liver, where it is converted to dobromanthranilic acid and glucuronic conjugates and excreted by the kidneys.

Indications

Acute, bronchitis with difficulty in sputum discharge, pneumoconiosis, bronchial asthma, tuberculosis and cystic fibrosis of the lungs, bronchiectasis, acute pneumonia, pleurisy, pulmonary emphysema, acute, prolonged and chronic sinusitis, chronic rhinitis.

Pharmacological effect

Ambrohexal is a drug that has mucolytic, secretolytic and expectorant effects, and the active ingredient of the drug is ambroxol.

The mechanism of action of this drug is associated with a decrease in sputum viscosity as a result of depolymerization of sputum mucopolysaccharides, which consists of breaking disulfide bonds in the molecules, enhancing the release of active hydrolyzing enzymes from Clark cells.

Ambrohexal also increases the activity of the cilia of the bronchial epithelium, and normalizes the ratio of all components of sputum and, therefore, stimulates its mucociliary transport. This facilitates expectoration of mucus from the respiratory tract, and also stimulates secretion and blocks the breakdown of surfactant.

Ambrohexal is quickly absorbed from the gastrointestinal tract, having a high absorption capacity, and its optimal plasma concentration is achieved within two hours after taking the drug: tablets, syrup, extended-release capsules and inhalation solution.

The effect of the drug occurs when taken in the form of syrup or tablets – after 30 minutes and depends on the rate of absorption of the drug in the stomach and intestines. Metabolism of this drug occurs in the liver, where it is converted to dobramantranilic acid and glucuronic conjugates, and is excreted by the kidneys.

Special instructions

Ambroxol should be used with caution in patients with a weakened cough reflex or impaired mucociliary transport due to the possibility of sputum accumulation.

Patients taking ambroxol should not be advised to perform breathing exercises; in seriously ill patients, aspiration of liquefied sputum should be performed.

In patients with bronchial asthma, ambroxol may increase cough.

You should not take ambroxol immediately before bed.

Ambroxol should not be taken simultaneously with antitussive drugs that can inhibit the cough reflex, such as codeine, because this may make it difficult to remove liquefied mucus from the bronchial tree.

Instructions for patients with diabetes: 1 tablet contains less than 0.01 XE.

Active ingredient

Ambroxol

Composition

One tablet contains:

Pregnancy

The drug is contraindicated for use during the first trimester of pregnancy.

The use of Ambrohexal® during pregnancy (II-III trimester) is possible only if the expected benefit to the mother outweighs the potential risk to the fetus or infant.

Ambroxol penetrates the placental barrier. Animal studies have shown that the drug has no effect on embryofetal development, childbirth and postnatal development.

Contraindications

Hypersensitivity to the components of the drug;
pregnancy (first trimester).
peptic ulcer of the stomach and duodenum

With caution: patients with renal and hepatic insufficiency.

Side Effects

From the digestive system: nausea, vomiting, gastralgia, diarrhea, constipation, dry mouth.

Allergic reactions: skin rash, urticaria, angioedema, bronchospasm attack, fever with chills; anaphylactic shock; weakness, headache, rhinorrhea, increased salivation, dry airways, difficulty urinating (dysuria).

Interaction

Combined use with antitussive drugs leads to difficulty in sputum discharge due to suppression of the cough reflex. Increases the penetration of amoxicillin, cefuroxime, erythromycin and doxycycline into the bronchial secretions.

Overdose

Symptoms: nausea, vomiting, gastralgia. There are reports of short-term anxiety and diarrhea. In case of severe overdose, blood pressure may drop.

Treatment: induction of vomiting, gastric lavage in the first 1–2 hours after taking the drug, administration of fat-containing foods.

Storage conditions

The drug should be stored at a temperature not exceeding 25°C.

Shelf life

2 years

Manufacturer

Salutas Pharma GmbH, Germany